Ruth was a fit and healthy woman who had never smoked, so the diagnosis of stage IV lung cancer came as a terrible shock to us all. The number of people diagnosed in the UK each year with non-smoking lung cancers is on the rise. The diagnosis is more common in women (twice that of men) and the under 55s.
Only 1 in 20 of those diagnosed survive over 10 years.
What We’re Doing
“Non-smoking lung cancers can affect anyone at any age. The Ruth Strauss Foundation is focused on the need for more research & collaborative working so that we can better understand how to diagnose, treat and even cure non-smoking related lung cancers.”
Raising awareness of non-smoking lung cancers.
Ruth strongly believed that by sharing knowledge, improvements in patient care and outcomes would be accelerated.
There is very little known about why non-smoking related lung cancers develop and a lack of co-ordinated funding to help progress the field.
We believe that joining up and sharing knowledge about non-smoking related lung cancers globally, including patient experiences, will help make those breakthroughs come sooner.
RSF has supported TracerX, a ground-breaking CRUK-funded lung cancer research programme.
Our next step is to facilitate a first-of-its-kind non-smoking related lung cancer workshop, bringing together global experts and researchers in lung cancer, to drive forward a strategy for how the world makes strides into better understanding non-smoking related lung cancers.
THE RESEARCH TEAM
As part of our research mission, our Research Advisory Group provide guidance and independent advice on matters related to the academic and medical fields of our projects, as well as advice on how to maximise their impact. We held our first Advisory Group meeting in January 2020, and plan to hold our next meeting in August 2020. We are delighted to have the expertise of the following members of the Research Advisory Group, and would like to thank them all for their time and ongoing encouragement and support:
He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships. His research interests include the development of novel drug strategies for the treatment of thoracic cancers through clinical trials, the identification of DNA variants that influence thoracic cancer development and their impact on clinical behaviour, as well as the identification of biomarkers predictive of therapeutic effect.
He is co-director for the NIHR London South Clinical Research Network (CRN) Cancer Division and Chair of Cancer for the West London Genomic Medicine Centre. He Chairs the British Thoracic Oncology Group (BTOG), and is past Chair of the UK NCRI Lung Cancer Clinical Studies Group (CSG) Advanced Disease Sub-group. He is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group, the European Thoracic Oncology Platform (ETOP), and the International Thymic Malignancy Interest Group (ITMIG).
He is referred hundreds of cases each year for diagnosis from clinicians and other pathologists. He is a past chair of the International Association for the Study of Lung Cancer (IASLC) Pathology Committee, as well as a member of the IASLC Staging and Prognostic Factors Committee. He is President Elect of the British Division of the International Academy of Pathologists.
Andrew has co-authored over 400 peer-reviewed publications, co-authored Pathology of the Lung (2011), the AFIP Atlas, Tumors of the Lower Respiratory Tract (2019), and was a Volume Editor of the 2015 WHO classification of lung, pleura, thymus and heart tumours.
Sandra is involved in clinical and scientific research. In 2009 she won a career development award from Sarcoma Alliance For Research Through Collaboration (SARC) to identify new targets for treatment for sarcoma and led a number of national and international clinical trials that aim to improve outcome for patients with these rare cancers. Sandra is a translational research partner within a european collaboration for patients with Ewing sarcoma and in 2017 was appointed clinical lead for sarcoma and rare cancers for the Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS). She is also a member of the Sarcoma UK Research Advisory Committee and frequently reviews grant applications for charities.
Reason for being involved
“As Ruth’s sister-in-law I saw at close hand the devastating effects of her diagnosis. Ruth was truly remarkable for her frank and honest approach to dealing with her illness, her ability to make the most of each day she had and her selflessness in preparing those close to her for a future without her. As an oncologist, I understand the unmet need in providing support for young patients with incurable cancer, and the value in working together to accelerate research.
Whether you join us at one of our events, support us by fundraising, cheer on our #RunforRuth runners by the sidelines or book a spot at one of our corporate events – your support is very much appreciated.
Your valuable donations will go towards vital support for families to help prepare for the death of a parent from cancer and raise much needed awareness of non-smoking lung cancers & the importance of its research.